Mesoblast Ryoncil revenue jumps 44% as cash spend improves
Alpha Vantage · The Motley Fool Australia · · AI-summarised by FinFlash
Mesoblast Ltd reported a 44% rise in Ryoncil net revenue to US$28 million for its first fiscal quarter, alongside an 85% improvement in net operating cash spend. The company credits the growth to increased penetration and adoption of Ryoncil, an FDA-approved therapy for children with steroid-refractory acute graft-versus-host disease.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.